Oral Supplementation of Turmeric Decreases Proteinuria, Hematuria, and Systolic Blood Pressure in Patients Suffering From Relapsing or Refractory Lupus Nephritis: A Randomized and Placebo-controlled Study

Khajehdehi, Parviz; Zanjaninejad, Batol; Aflaki, Elham; Nazarinia, Mohammad Ali; Azad, F.; Malekmakan, Leila; Dehghanzadeh, Gholamreza

doi:10.1053/j.jrn.2011.03.002

Cited by 126 publications

(97 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Turmeric powder (500 mg capsules), administered to patients with refractory lupus nephritis, was shown to significantly ameliorate proteinuria. 58 Thus, there is a precedence for protection by CU/TU against proteinuria and glomerulonephritis. Drastically reduced lymphadenopathy in the lpr-CU and lpr-TU groups We observed a dramatic reduction in lymphadenopathy in both lpr-CU and lpr-TU groups compared with the lpr-water group, with lpr-TU having the most decrease (figure 2bA, bB).…”

Section: Discussionmentioning

confidence: 99%

Significantly reduced lymphadenopathy, salivary gland infiltrates and proteinuria in MRL-lpr/lprmice treated with ultrasoluble curcumin/turmeric: increased survival with curcumin treatment

et al. 2015

View full text Add to dashboard Cite

ObjectivesCommercial curcumin (CU), derived from food spice turmeric (TU), has been widely studied as a potential therapeutic for a variety of oncological and inflammatory conditions. Lack of solubility/bioavailability has hindered curcumin's therapeutic efficacy in human diseases. We have solubilised curcumin in water applying heat/pressure, obtaining up to 35-fold increase in solubility (ultrasoluble curcumin (UsC)). We hypothesised that UsC or ultrasoluble turmeric (UsT) will ameliorate systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS)-like disease in MRL-lpr/lpr mice.MethodsEighteen female MRL-lpr/lpr (6 weeks old) and 18 female MRL-MpJ mice (6 weeks old) were used. Female MRL-lpr/lpr mice develop lupus-like disease at the 10th week and die at an average age of 17 weeks. MRL-MpJ mice develop lupus-like disease around 47 weeks and typically die at 73 weeks. Six mice of each strain received autoclaved water only (lpr-water or MpJ-water group), UsC (lpr-CU or MpJ-CU group) or UsT (lpr-TU or MpJ-TU group) in the water bottle.ResultsUsC or UsT ameliorates SLE in the MRL-lpr/lpr mice by significantly reducing lymphoproliferation, proteinuria, lesions (tail) and autoantibodies. lpr-CU group had a 20% survival advantage over lpr-water group. However, lpr-TU group lived an average of 16 days shorter than lpr-water group due to complications unrelated to lupus-like illness. CU/TU treatment inhibited lymphadenopathy significantly compared with lpr-water group (p=0.03 and p=0.02, respectively) by induction of apoptosis. Average lymph node weights were 2606±1147, 742±331 and 385±68 mg, respectively, for lpr-water, lpr-CU and lpr-TU mice. Transferase dUTP nick end labelling assay showed that lymphocytes in lymph nodes of lpr-CU and lpr-TU mice underwent apoptosis. Significantly reduced cellular infiltration of the salivary glands in the lpr-TU group compared with the lpr-water group, and a trend towards reduced kidney damage was observed in the lpr-CU and lpr-TU groups.ConclusionsThese studies show that UsC/UsT could prove useful as a therapeutic intervention in SLE/SS.

show abstract

Section: Discussionmentioning

confidence: 99%

Significantly reduced lymphadenopathy, salivary gland infiltrates and proteinuria in MRL-lpr/lprmice treated with ultrasoluble curcumin/turmeric: increased survival with curcumin treatment

et al. 2015

View full text Add to dashboard Cite

show abstract

“…In addition, turmeric (curcumin) has potential in the prevention and treatment of neurodegenerative diseases as a free radical scavenger, including Alzheimer's disease [34,36]. Moreover, short-term supplementation of turmeric has been reported to decrease proteinuria, hematuria, and systolic blood pressure in patients with relapsed or refractory lupus nephritis and can be used as a safe adjuvant therapy for the patients [37]. Overall, our study indicates that the high antioxidant properties of turmeric from Bangladesh may inhibit cellular lipid peroxidation and ameliorate other oxidative damage caused by free radicals [32].…”

Section: Frapmentioning

confidence: 99%

Antioxidant Properties of Popular Turmeric(Curcuma longa)Varieties from Bangladesh

Tanvir

Hossen

Hossain

et al. 2017

Journal of Food Quality

198

109

View full text Add to dashboard Cite

We investigated the aqueous and ethanolic extracts of different forms (local names: mura and chora) of turmeric (Curcuma longa) from the Khulna and Chittagong divisions of Bangladesh for their antioxidant properties and polyphenol, flavonoid, tannin, and ascorbic acid contents. The antioxidant activity was determined using the 1,1-diphenyl-2-picrylhydrazyl (DPPH) free radicalscavenging activity and ferric reducing antioxidant power (FRAP) values. The ethanolic extract of Chittagong's mura contained the highest concentrations of polyphenols (16.07%), flavonoids (9.66%), and ascorbic acid (0.09 mg/100 g) and chora resulted in high yields (17.39%). The ethanolic extract of Khulna's mura showed a higher DPPH radical-scavenging activity with the lowest 50% inhibitory concentration (IC 50 ) (1.08 g/mL), while Khulna's chora had the highest FRAP value (4204.46 ± 74.48 M Fe [II] per 100 g). Overall, the ethanolic extract had higher antioxidant properties than those in the aqueous extract. However, the tannin concentration was lower in the ethanolic extract. We conclude that the turmeric varieties investigated in this study are useful sources of natural antioxidants, which confer significant protection against free radical damage.

show abstract

“…Inflammatory bowel disease (IBD) consists of two separate diseases, CD and ulcerative colitis (UC); both characterized by chronic recurrent ulceration of the bowel (Kozuch and Oppenheimer, 19371972Diabetes Srinivasan, 19721980 Rheumatoid arthritis Deodhar et al, 1980Deodhar et al, 1986 Post-operative inflammation Satoskar et al, 1986Satoskar et al, 1987 Cancer lesions Kuttan et al, 1987Kuttan et al, 1992 Lung cancer Polasa et al, 1992Polasa et al, 1992 Atherosclerosis Kuttan, 1992 1993 Gastric ulcer Kositchaiwat et al, 1993Kositchaiwat et al, 1996 Acquired immunodeficiency syndrome James, 1996James, 1997 Cancer lesions Hastak et al, 1997Hastak et al, 1999 Biliary dyskinesia Niederau and Gopfert, 1999 Khajehdehi et al, 2012 BJP B B Aggarwal et al Hanauer, 2008). It is likely that the pathogenesis of these diseases involves genetic, environmental and immunological factors (Hanauer, 1996).…”

Section: Inflammatory Bowel Diseasementioning

confidence: 99%

Curcumin: an orally bioavailable blocker of TNF and other pro‐inflammatory biomarkers

Aggarwal

Gupta

Sung

2013

British J Pharmacology

343

239

View full text Add to dashboard Cite

TNFs are major mediators of inflammation and inflammation-related diseases, hence, the United States Food and Drug Administration (FDA) has approved the use of blockers of the cytokine, TNF-a, for the treatment of osteoarthritis, inflammatory bowel disease, psoriasis and ankylosis. These drugs include the chimeric TNF antibody (infliximab), humanized TNF-a antibody (Humira) and soluble TNF receptor-II (Enbrel) and are associated with a total cumulative market value of more than $20 billion a year. As well as being expensive ($15 000-20 000 per person per year), these drugs have to be injected and have enough adverse effects to be given a black label warning by the FDA. In the current report, we describe an alternative, curcumin (diferuloylmethane), a component of turmeric (Curcuma longa) that is very inexpensive, orally bioavailable and highly safe in humans, yet can block TNF-a action and production in in vitro models, in animal models and in humans. In addition, we provide evidence for curcumin's activities against all of the diseases for which TNF blockers are currently being used. Mechanisms by which curcumin inhibits the production and the cell signalling pathways activated by this cytokine are also discussed. With health-care costs and safety being major issues today, this golden spice may help provide the solution. LINKED ARTICLESThis article is part of a themed section on Emerging Therapeutic Aspects in Oncology. To view the other articles in this section visit http://dx

show abstract

Oral Supplementation of Turmeric Decreases Proteinuria, Hematuria, and Systolic Blood Pressure in Patients Suffering From Relapsing or Refractory Lupus Nephritis: A Randomized and Placebo-controlled Study

Cited by 126 publications

References 32 publications

Significantly reduced lymphadenopathy, salivary gland infiltrates and proteinuria in MRL-lpr/lprmice treated with ultrasoluble curcumin/turmeric: increased survival with curcumin treatment

Significantly reduced lymphadenopathy, salivary gland infiltrates and proteinuria in MRL-lpr/lprmice treated with ultrasoluble curcumin/turmeric: increased survival with curcumin treatment

Antioxidant Properties of Popular Turmeric(Curcuma longa)Varieties from Bangladesh

Curcumin: an orally bioavailable blocker of TNF and other pro‐inflammatory biomarkers

Contact Info

Product

Resources

About